BioSpace News Archive

Fate Therapeutics, Inc. announced that on April 1, 2024 the Company granted restricted stock units representing 6,400 shares of its common stock to one newly-hired non-executive employee.

Renibus Therapeutics® (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference, being held in a virtual format, April 8-11, 2024.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the launch of its ENROUTE® Transcarotid Neuroprotection System PLUS (“NPS PLUS”), a key component of the TCAR® portfolio.

Oncoinvent AS announced the appointment of newly elected members of its Board of Directors and the formation of a Scientific and Clinical Advisory Board under the leadership of founding scientists Roy Larsen and Øyvind Bruland, previous board members and leading experts in oncology and pharmaceutical development.

Praxis Precision Medicines, Inc. announced that on April 1, 2024, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase 300 shares of its common stock and restricted stock unit awards covering 225 shares of its common stock to one new non-executive employee under the Praxis Precision Medicines, Inc. 2024 Inducement Plan.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved Fanapt® (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

Bristol Myers Squibb announced that the European Commission has expanded approval of Reblozyl® to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes.

RemeGen Co. Ltd., a commercial-stage biotechnology company, obtained Fast Track Designation by the United States Food and Drug Administration recently for its innovative BLyS/APRIL dual-target fusion protein drug, Telitacicept, independently developed by RemeGen for the treatment of patients with primary Sjögren’s syndrome.

Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has entered a collaborative research agreement with TiCARos Co Ltd

EpicentRx, Inc today announced that an abstract on its lead therapy, AdAPT-001, will be presented at the American Association for Cancer Research (AACR) Annual Meeting to be held in San Diego, CA from April 5-10, 2024.